Throughout November, we gained some fascinating new insights into the potential of psychedelic medicine as researchers from some of the world’s leading institutions published their work. The month brought with it exciting new psychedelic research and some long-awaited results. Most notably, the official results of COMPASS Pathways‘ Phase IIb trial exploring the use of psilocybin in treating…


Previous articlePsychedelics Weekly – Cannabis as an Adjunct Cancer Treatment & 5-MeO-DMT Reactivations
Next articlePsychedelic Bulletin #125: New Data Boosts Spravato’s Case; Bipartisan Breakthrough Therapies Act; Berkeley Could Decrim. Psychedelics; DEA Increases Production Quotas